Organization | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Beijing China (1991)

Status: No NME R&D (1991)

Organization Overview

First Clinical Trial

2007

NCT01014845

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Xiamen Innovax Biotech Co., Ltd

Active Ingredients

Drugs in Phase 4 Trials (4)

cecolin (2 trials)

hecolin (1 trial)

hepatitis e vaccine (9 trials)

hpv 16/18 vaccine (Cervarix) (4 trials)

Drugs in Phase 3 Trials (3)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (4 trials)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (3 trials)

recombinant human papillomavirus nonavalent (types 6,11,16,18,31,33,45,52,58 )vaccine(e.coli) (2 trials)

Drugs in Phase 2 Trials (1)

recombinant human papillomavirus virus type 6/11 bivalent vaccine (1 trial)

Drugs in Phase 1 Trials (1)

aluminum (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma in Situ (Phase 3)

Cervical Intraepithelial Neoplasia (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis E (Phase 4)

Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 20
# of Trial APIs: 9